Text Size

Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis

This study is currently recruiting participants.
Verified August 2011 by Analgesic Solutions
Sponsor:
Collaborator:
Forest Laboratories
Information provided by:
Analgesic Solutions
ClinicalTrials.gov Identifier:
NCT01329406
First received: April 4, 2011
Last updated: August 16, 2011
Last verified: August 2011
History of Changes
  Purpose

The present study will aim to evaluate the efficacy of milnacipran in the treatment of pain due to osteoarthritis (OA), that is, to determine whether milnacipran provides superior efficacy to placebo in patients with OA. Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is currently approved in the United States in the treatment of major depressive disorder and fibromyalgia. There is increased evidence to suggest that SNRIs may be effective in the treatment of chronic pain conditions, such as OA.

The hypothesis in this study is that the survival time (time from randomization to loss of efficacy) of milnacipran group is superior to that of placebo group.


Condition Intervention Phase
Osteoarthritis
 Drug: Milnacipran
Drug: Placebo
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis

Resource links provided by NLM:

MedlinePlus related topics: Osteoarthritis
U.S. FDA Resources

Further study details as provided by Analgesic Solutions:

Primary Outcome Measures:
  • Time to loss of efficacy in the Double-Blind Period [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    The time to pain worsening by 30% compared to the value at baseline and a pain score of at least 4 on the 0-10 numerical rating scale on weekly pain assessment. Subjects who drop out due to "lack of efficacy" will be counted as efficacy failures regardless of their pain scores.


Secondary Outcome Measures:
  • Mean change in pain intensity [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Mean change in pain intensity on the 0-10 numerical rating scale from baseline in the Double-Blind Period.

  • Mean change in Western Ontario and McMaster Osteoarthritis Index (WOMAC) scores [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    Mean change in Western Ontario and McMaster Osteoarthritis Index (WOMAC) scores from Baseline in the Open-Label Period and Double-Blind Period.

  • The efficacy of milnacipran vs. placebo by time to dropout for all causes [ Time Frame: 70 days ] [ Designated as safety issue: No ]
  • The efficacy of milnacipran in the Open-Label Period [ Time Frame: 28 days ] [ Designated as safety issue: No ]
    The efficacy of milnacipran in the Open-Label Period defined by the change in pain intensity from Baseline to the end of the period and responder proportion.

  • The difference between milnacipran and placebo in responder proportion in the Double-Blind Period [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • The predictive value of "OA sensory sub-type" for predicting the response to milnacipran vs. placebo [ Time Frame: 70 days ] [ Designated as safety issue: No ]
  • Safety and tolerability by monitoring adverse events [ Time Frame: 70 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: July 2011
Estimated Study Completion Date: September 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Milnacipran
If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The milnacipran arm will take milnacipran at 200mg/day (100mg twice daily).
 Drug: Milnacipran
1 tablet (100mg) by mouth twice daily for 28 days
Placebo Comparator: Placebo
If subjects meet the criteria to enter the Double-Blind Period, they will be randomized at a 1:1 ratio to take either milnacipran or placebo for 4 weeks. The placebo group will take 1 tablet twice daily.
 Drug: Placebo
1 tablet by mouth twice daily for 28 days

Detailed Description:

The study design is a Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study. This means that, upon entry into the study, all subjects will enter an open-label period during which they will take milnacipran for 4 weeks. Subjects will taper their dose up to one 100mg tablet twice daily for a total of 200mg per day. After 4 weeks, the subject will return to the clinic and be re-evaluated.

Only subjects who meet certain criteria are then randomized to continue in the double-blind period of the study. Once a subject is randomized, he or she will take either milnacipran or placebo for another 4 weeks. Following the double-blind period, subjects will be tapered off the study medication and will receive a phone call once each week for 2 weeks for follow-up assessments.

Throughout the study, subjects will complete various questionnaires and other test procedures aimed at sub-typing subjects based on pain mechanisms.

  Eligibility

Ages Eligible for Study:   21 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Be 21-75 years of age and in good general medical and psychological health
  • Be able to speak, read, write, and understand English, understand the consent form, complete study related procedures, and communicate with the study staff
  • Have a negative urine pregnancy test at screening, and use appropriate birth control

  • Have documented painful Osteoarthritis (OA) of at least one knee for at least 6 months; OA should be of Class I-III and meet the American College of Rheumatology (ACR) clinical classification criteria, defined as:

    1. Knee pain and at least 3 of the following 6:

      • Age > 50
      • Morning stiffness < 30 minutes
      • Crepitus on active motion
      • Bony tenderness
      • Bony enlargement
      • No palpable warmth of synovium
    2. The target joint must not contain any type of orthopedic and/or prosthetic device
  • Have a target joint pain average of 5 days per week and have an average pain intensity of at least 4/10 on the 0-10 NRS over the last 24 hours prior to screening
  • Have stable treatment modalities, e.g. acupuncture, physical therapy
  • Be willing to stop taking Non-steroidal Anti-inflammatory drugs (NSAIDs) and opioids for the duration of the study

Exclusion Criteria:

  • Are allergic or intolerant to SNRI; have a previous poor response to a SNRI for OA pain; are currently taking an SNRI or tricyclic antidepressant
  • Have a body mass index (BMI) >40 kg/m2
  • Have an Hospital Anxiety and Depression Scale (HADS) score >12 on either subscale or has an established history of major depressive disorder not controlled with medication
  • Have significant pain outside the target knee, including significant hip or back pain. (Bilateral knee OA allowed.)
  • Have pain affecting the target knee that is due to any other etiology than OA
  • Have documented history of inflammatory arthritis including rheumatoid arthritis
  • Have had local injections in target joint within the past 3 months prior to screening
  • Have had oral or intramuscular corticosteroids within the past 30 days
  • Have had worker's compensation claim, disability, or litigation
  • Have a known history of uncontrolled narrow-angle glaucoma
  • Have a known history of suicidal ideation
  • Use monoamine oxidase inhibitors (MAOI) concomitantly
  • Are allergic or intolerant to acetaminophen
  • Using opioids 4 or more days per week during the month preceding the screening visit
  • Have significant history or renal impairment/failure.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01329406

Locations
United States, Massachusetts
Analgesic Solutions Recruiting
Natick, Massachusetts, United States, 01760
Contact: Karen Cowles, RN, MPH     781-444-9605 ext 121     kcowles@analgesicsolutions.com    
Contact: Courtney Lincoln     781-444-9605 ext 119     clincoln@analgesicsolutions.com    
Principal Investigator: Stephen L. Wright, M.D.            
Sub-Investigator: Nathaniel P. Katz, M.D., M.S.            
Sub-Investigator: Eric Osgood, M.D.            
Sponsors and Collaborators
Analgesic Solutions
Forest Laboratories
Investigators
Principal Investigator: Stephen L. Wright, M.D. Analgesic Solutions
  More Information

No publications provided

Responsible Party: Stephen Wright, M.D., Principal Investigator, Analgesic Solutions
ClinicalTrials.gov Identifier: NCT01329406     History of Changes
Other Study ID Numbers: FRX001-2010
Study First Received: April 4, 2011
Last Updated: August 16, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Analgesic Solutions:
Osteoarthritis (OA)
Milnacipran
Serotonin-norepinephrine reuptake inhibitor (SNRI)
Knee pain

Additional relevant MeSH terms:
Osteoarthritis
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Milnacipran
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
 Pharmacologic Actions
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin Agents
Physiological Effects of Drugs
Adrenergic Uptake Inhibitors
Adrenergic Agents

ClinicalTrials.gov processed this record on May 21, 2013